Sakalis Vasileios I, Oliver Rachel, Guy Peter J, Davies Melissa C
a Department of Urology , Salisbury NHS Foundation Trust , Salisbury , UK.
J Spinal Cord Med. 2019 Jul;42(4):478-484. doi: 10.1080/10790268.2018.1433266. Epub 2018 Feb 7.
CONTEXT/OBJECTIVE: Vesico-ureteric reflux(VUR) is a known complication of neuropathic bladder in spinal cord injury(SCI) population. Bulking agents such as Macroplastique are new minimally-invasive treatment option for VUR with good results. The aim of this study is to assess the efficacy of Macroplastique alone or in combination with Botox(BTX-A), in managing VUR in SCI population with presumed healthy bladders and correlate the pre-and post-injection urodynamic findings with the outcome.
Retrospective comparative study.
SCI patients with VUR and presumed health bladders (normo-compliant, low filling pressures), treated with macroplastique alone or in combination with BTX-A, who had pre and post-intervention Video-urodynamics (VUDS) and followed up for at least 12 months.
Macroplastique and BTX-A injections, VUDS.
The primary end point was the overall treatment rate of VUR at 3 months and the secondary outcomes were the success rate (treated + improved) and the comparison of urodynamic parameters (pre-and post-injection).
We studied 34 intervention-naïve SCI patients. 19 had only Macroplastique (Group 1) and 15 had Macroplastique and BTX-A (Group 2). The overall treatment rate was 65.4% for group 1 and 88.9% for group 2 (P = 0.029). The overall success rate (treated + improved) was 80.8% and 94.4% respectively (P = 0.123). The comparison of follow up VUDS parameters showed a statistically significant rise in the detrusor pressure of group 1 (34.04cmH2O vs.19.2cmH2O, P = 0.008) and a drop in compliance (19.8mls/cmH2O vs.26.3mls/cmH2O, P = 0.018) as compared to baseline.
The combination of BTX-A and Macroplastique is more effective that Macroplastique alone in the management of secondary VUR in SCI patients with presumed healthy bladders.
背景/目的:膀胱输尿管反流(VUR)是脊髓损伤(SCI)患者神经源性膀胱的一种已知并发症。诸如Macroplastique之类的填充剂是治疗VUR的新型微创治疗选择,效果良好。本研究的目的是评估单独使用Macroplastique或联合肉毒杆菌毒素(BTX-A)治疗假定膀胱健康的SCI患者VUR的疗效,并将注射前后的尿动力学检查结果与治疗结果相关联。
回顾性比较研究。
患有VUR且假定膀胱健康(顺应性正常、充盈压较低)的SCI患者,接受单独的Macroplastique或联合BTX-A治疗,干预前后均进行了影像尿动力学检查(VUDS),并随访至少12个月。
注射Macroplastique和BTX-A,进行VUDS检查。
主要终点是3个月时VUR的总体治疗率,次要终点是成功率(治疗有效+改善)以及尿动力学参数的比较(注射前后)。
我们研究了34例初治SCI患者。19例仅接受Macroplastique治疗(第1组),15例接受Macroplastique联合BTX-A治疗(第2组)。第1组的总体治疗率为65.4%,第2组为88.9%(P = 0.029)。总体成功率(治疗有效+改善)分别为80.8%和94.4%(P = 0.123)。随访VUDS参数比较显示,与基线相比,第1组逼尿肌压力有统计学意义的升高(34.04cmH₂O对19.2cmH₂O,P = 0.008),顺应性下降(19.8mls/cmH₂O对26.3mls/cmH₂O,P = 0.018)。
在治疗假定膀胱健康的SCI患者继发性VUR方面,BTX-A与Macroplastique联合使用比单独使用Macroplastique更有效。